Erectile Dysfunction Drugs Market to Reach $5.1 Billion, Globally, by 2032 at 6.5% CAGR: Allied Market Research
May 11, 2023 10:13 ET
|
Allied Market Research
Portland, OR, May 11, 2023 (GLOBE NEWSWIRE) -- Allied Market Research published a report, titled, “Erectile Dysfunction Drugs Market By Product (Sildenafil, Avanfil, Tadalafil, Udenafil, and...
Over 20 Million Suffer From Peripheral Neuropathy, St. Pete Medical Group Aims to Help
December 14, 2022 12:30 ET
|
St. Pete Medical Group
ST. PETERSBURG, Fla., Dec. 14, 2022 (GLOBE NEWSWIRE) -- St. Pete Medical Group and Clearwater Medical Group were featured on 10 Tampa Bay's Great Day Live. Dr. Alex Spinoso announced their mission...
Zylö Receives $263,000 NIH Phase I Grant to Develop a Topical Viagra® for ED
September 16, 2022 08:30 ET
|
Zylö Therapeutics
Funds to be used to optimize a formulation and demonstrate comparable efficacy to oral Viagra GREENVILLE, SC, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Zylö Therapeutics Inc., developer of the Z-pod®...
Oncotelic Presenting Data for OT101 Against Diffuse Intrinsic Pontine Glioma (DIPG) at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting
September 14, 2022 08:15 ET
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), developer of treatments for rare and orphan indications, including...
ONCOTELIC ACQUIRES FAST TO MARKET LATE-STAGE DRUG CANDIDATE FOR PARKINSON DISEASE, ERECTILE DYSFUNCTION, AND FEMALE SEXUAL DYSFUNCTION.
October 04, 2021 07:00 ET
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), executed an exclusive licensing agreement on September 30, 2021,...
ONCOTELIC TO ACQUIRE LATE-STAGE DRUG CANDIDATE FOR PARKINSON DISEASE, ERECTILE DYSFUNCTION, AND FEMALE SEXUAL DYSFUNCTION.
September 01, 2021 12:00 ET
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC), executed a binding term sheet with Autotelic Inc. to license AL-101...
Zylö Receives $1,700,000 NIH Phase II Grant to Advance Erectile Dysfunction Program into Human Trials
July 20, 2021 09:00 ET
|
Zylö Therapeutics
Funds to be used for scale-up, implementation of cGMP quality system, and pre-IND FDA meeting GREENVILLE, SC, July 20, 2021 (GLOBE NEWSWIRE) -- Zylö Therapeutics Inc., developer of the...
US Erectile Dysfunction Market and Competitive Landscape Report 2021: Epidemiology, Key Products Marketed, Market Valuations and Forecast, Drugs Sales and Market Shares
June 08, 2021 04:58 ET
|
Research and Markets
Dublin, June 08, 2021 (GLOBE NEWSWIRE) -- The "US Erectile Dysfunction Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering. US Erectile Dysfunction...
Leonhardt Ventures LLC Announces Plans To Take Bids for MyoStim ED ErectiStim TM Erectile Dysfunction IP and Assets
June 02, 2021 11:32 ET
|
Leonhardt Ventures LLC
United States, California, Newport Beach, June 02, 2021 (GLOBE NEWSWIRE) -- -- Leonhardt Ventures LLC and it's innovation accelerator subsidiary Leonhardt's Launchpads by Cal-X Stars...
CURE Pharmaceutical [OTCQB:CURR] Secures Chinese Patent on its Oral Thin Films to Treat Erectile Dysfunction
March 17, 2020 08:30 ET
|
Cure Pharmaceutical Holding Corp.
OXNARD, Calif., March 17, 2020 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTC:CURR), an innovative drug delivery and development company, today announced the allowance of Chinese Patent No....